Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase of over 24% despite a previous decline of over 25% in the two days following its inclusion in the Hong Kong Stock Connect program, indicating a positive market reaction to recent announcements [1] Group 1: Stock Performance - As of the latest update, Silver诺医药-B's stock price rose by 23.38%, reaching HKD 39.44, with a trading volume of HKD 76.49 million [1] Group 2: Inclusion in Stock Connect - Silver诺医药-B has been included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025 [1] - The board believes that this inclusion will expand the company's investor base and increase the trading liquidity of its H-shares, thereby enhancing the investment value of H-shares and the company's reputation in the capital market [1] Group 3: Product Development - The company announced that its self-developed long-acting GLP-1 receptor agonist, Irsuglutide α (怡诺轻), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented from January 1, 2026 [1] - Irsuglutide α (怡诺轻) is characterized by a long half-life, low dosing frequency, and blood glucose-dependent regulation, making it the third globally and the first in Asia to enter the commercialization stage among long-acting GLP-1 receptor agonists [1] - This product is also noted as the first innovative drug of its kind developed in China, providing high-quality treatment options for type 2 diabetes patients [1]